آسیب شدید نورون‌های دپامینرژیک جسم سیاه همراه با کاهش سطح سرمی مس می‌باشد

Mullin S, Schapira AH. Pathogenic mechanisms of neurodegeneration in Parkinson disease. Neurologic Clinics 2015;33:1-17. doi: 10.1016/j.ncl.2014.09.010

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers 2017;3:1-21. doi: 10.1038/nrdp.2017.13

Harris RE. Epidemiology of chronic disease: global perspectives: Jones & Bartlett Learning. 2nd ed;2019.ISBN-10:1284151018

Brooks DJ. Parkinson's disease: diagnosis. Parkinsonism & Related Disorders 2012;18:S31-S3. doi: 10.1016/S1353-8020(11)70012-8

Alberio T, Bucci EM, Natale M, Bonino D, Di Giovanni M, Bottacchi E, et al. Parkinson's disease plasma biomarkers: an automated literature analysis followed by experimental validation. J Proteomics 2013;90:107-14. doi: 10.1016/j.jprot.2013.01.025

Grabrucker A, Rowan M, C Garner C. Brain-delivery of zinc-ions as potential treatment for neurological diseases: mini review. Drug Deliv Lett 2011;1:13-23. doi: 10.2174/2210303111101010013

Genoud S, Senior AM, Hare DJ, Double KL. Meta‐analysis of copper and iron in parkinson's disease brain and biofluids. Mov Disord 2020;35:662-71. doi: 10.1002/mds.27947

Moemeni H, Qujeq D, Ahmadi Ahangar A, Hajian K, Parsian H. Evaluation of serum Magnesium, Iron, Copper and Zinc levels in ischemic and hemorrhagic stroke patients and healthy controls. J Clinic Basic Res 2018;2:6-10. doi: 10.29252/jcbr.2.1.6

Sensi SL, Granzotto A, Siotto M, Squitti R. Copper and zinc dysregulation in Alzheimer’s disease. Trends Pharmacol Sci 2018;39:1049-63. doi: 10.1016/j.tips.2018.10.001

Wolozin B, Golts N. Iron and Parkinson’s disease. Review. The Neuroscientist 2002;8:22-32. doi: 10.1177/107385840200800107

Binolfi A, Rodriguez EE, Valensin D, D’Amelio N, Ippoliti E, Obal G, et al. Bioinorganic chemistry of Parkinson’s disease: structural determinants for the copper-mediated amyloid formation of alpha-synuclein. Inorg Chem 2010;49:10668-79. doi: 10.1021/ic1016752

Vaz FNC, Fermino BL, Haskel MVL, Wouk J, de Freitas GBL, Fabbri R, et al. The relationship between copper, iron, and selenium levels and Alzheimer disease. Biol Trace Elem Res 2018;181:185-91. doi: 10.1007/s12011-017-1042-y

Fukushima T, Tan X, Luo Y, Kanda H. Serum vitamins and heavy metals in blood and urine, and the correlations among them in Parkinson’s disease patients in China. Neuroepidemiology 2011;36:240-4. doi: 10.1159/000328253

Younes-Mhenni S, Aissi M, Mokni N, Boughammoura-Bouatay A, Chebel S, Frih-Ayed M, et al. Serum copper, zinc and selenium levels in Tunisian patients with Parkinson’s disease. Tunis Med 2013;91:402-5.

Gangania MK, Batra J, Kushwaha S, Agarwal R. Role of Iron and Copper in the Pathogenesis of Parkinson’s Disease. Indian J Clin Biochem 2017;32:353-6. doi: 10.1007/s12291-016-0614-5

Kocatürk PA, Akbostanci MC, Tan F, Kavas GÖ. Superoxide dismutase activity and zinc and copper concentrations in Parkinson’s disease. Pathophysiology 2000;7:63-7. doi: 10.1016/s0928-4680(00)00030-4

Hegde ML, Shanmugavelu P, Vengamma B, Rao TS, Menon RB, Rao RV, et al. Serum trace element levels and the complexity of inter-element relations in patients with Parkinson's disease. J Trace Elem Med Biol 2004;18:163-71. doi: 10.1016/j.jtemb.2004.09.003

Meamar R, Nikyar H, Dehghani L, Basiri K, Ghazvini MRA. Assessing of plasma levels of iron, zinc and copper in Iranian Parkinson's disease. Adv Biomed Res 2016;5:31. doi: 10.4103/2277-9175.178788

Vural H, Demirin H, Kara Y, Eren I, Delibas N. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer’s disease. Journal of Trace Elements in Medicine and Biology 2010;24:169-73. doi: 10.1016/j.jtemb.2010.02.002

Gellein K, Syversen T, Steinnes E, Nilsen TIL, Dahl OP, Mitrovic S, et al. Trace elements in serum from patients with Parkinson's disease—a prospective case-control study: The Nord-Trøndelag Health Study (HUNT). Brain Res 2008;1219:111-5. doi: 10.1016/j.brainres.2008.05.002

Younes-Mhenni S, Aissi M, Mokni N, Boughammoura-Bouatay A, Chebel S, Frih-Ayed M, et al. Serum copper, zinc and selenium levels in Tunisian patients with Parkinson’s disease. Tunis Med 2013;91:402-5.

Blum D, Torch S, Lambeng N, Nissou M-F, Benabid A-L, Sadoul R, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001;65:135-72. doi: 10.1016/s0301-0082(01)00003-x

Hettinger BD, Lee A, Linden J, Rosin DL. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 2001;431:331-46. doi: 10.1002/1096-9861(20010312)431:3<331::aid-cne1074>3.0.co;2-w

Scigliano G, Girotti F, Soliveri P, Musicco M, Radice D, Caraceni T. Increased plasma bilirubin in Parkinson patients on L-dopa: evidence against the free radical hypothesis? Ital J Neurol Sci 1997;18:69-72. doi: 10.1007/BF01999565

Songsomboon C, Tanprawate S, Soontornpun A, Wantaneeyawong C, Louthrenoo W. Serum uric acid, serum uric acid to serum creatinine ratio and serum bilirubin in patients with parkinson’s disease: a case-control study. J Clin Med Res 2020;12:172-9. doi: 10.14740/jocmr4079

Forte G, Bocca B, Senofonte O, Petrucci F, Brusa L, Stanzione P, et al. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson’s disease. J Neural Transm 2004;111:1031-40. doi: 10.1007/s00702-004-0124-0

Nikam S, Nikam P, Ahaley S. Role of free radical and antioxidant imbalance in pathogenesis of Parkinson’s disease. Biomed Res 2009;20:55-8.

Ilyechova EY, Miliukhina IV, Orlov IA, Muruzheva ZM, Puchkova LV, Karpenko MN. A low blood copper concentration is a co-morbidity burden factor in Parkinson’s disease development. Neurosci Res 2018;135:54-62. doi: 10.1016/j.neures.2017.11.011

Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909. doi: 10.1016/s0896-6273(03)00568-3

Sarukhani MR, Haghdoost-Yazdi H, Khandan-Chelarci G. changes in the serum urate level can predict the development of parkinsonism in the 6-hydroxydopamine animal model. Neurochem Res 2018;43:1086-95. doi: 10.1007/s11064-018-2522-y

Sophiabadi M, Rastgoo N, Haghdoost-Yazdi H. dopaminergic neuronal death in substantia nigra associates with serum levels of total bilirubin, selenium, and zinc: evidences from 6-hydroxydopamine animal model of parkinson’s disease. Biol Trace Elem Res 2022;200:4058-4067. doi: 10.1007/s12011-021-03012-6

Sarbazi-Golezari A, Haghdoost-Yazdi H. Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta. Metab Brain Dis 2022;37:373-381. doi: 10.1007/s11011-021-00868-4

Paxinos G and Watson C. The rat brain in stereotaxic coordinates. 6th ed. 2007;San Diego, CA: Academic Press.

Minaei A, Haghdoost-Yazdi H. Dexmedetomidine attenuates the induction and reverses the progress of 6-hydroxydopamine- induced Parkinsonism; involvement of KATP channels, alpha 2 adrenoceptors and anti-inflammatory mechanisms. Toxicol Appl Pharmacol 2019;382:114743. doi: 10.1016/j.taap.2019.114743

Prasad EM, Hung SY. Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson's disease. Antioxidants 2020;9:1007. doi: 10.3390/antiox9101007

Yuan H, Sarre S, Ebinger G, Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 2005;144:35-45. doi: 10.1016/j.jneumeth.2004.10.004

Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005;162:1-10. doi: 10.1016/j.bbr.2005.02.023

Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76. doi: 10.1136/jnnp.2007.131045

Shulman LM, Gruber‐Baldini AL, Anderson KE, Vaughan CG, Reich SG, Fishman PS, et al. The evolution of disability in Parkinson disease. Mov Disord 2008;23:790-6. doi: 10.1002/mds.21879

Zhao H-W, Lin J, Wang X-B, Cheng X, Wang J-Y, Hu B-L, et al. Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson’s disease. PLoS One 2013;8:e83060. doi: 10.1371/journal.pone.0083060